Achillion Pharmaceuticals, Inc.
MarketLine (a Datamonitor Company)
08 Jan 2014
Available for Immediate Download
Achillion Pharmaceuticals, Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360° view of the company. Features: - Detailed information on Achillion Pharmaceuticals, Inc. required for business and competitor intelligence needs - A study of the major internal and external factors affecting Achillion Pharmaceuticals, Inc. in the form of a SWOT analysis - An in-depth view of the business model of Achillion Pharmaceuticals, Inc. including a breakdown and examination of key business segments - Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for Achillion Pharmaceuticals, Inc. - Intelligence on Achillion Pharmaceuticals, Inc.nv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about Achillion Pharmaceuticals, Inc., such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: Achillion Pharmaceuticals (Achillion or ‘the company’) is a biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of infectious diseases such as chronic hepatitis C virus (HCV) and resistant bacterial infections. The company operates in the US where it is headquartered in New Haven, Connecticut. Achillion had 56 full-time employees and one part-time employee as of February 11, 2013. The company recorded revenues of $2.6 million during the financial year ended December 2012 (FY2012), an increase of 5.5% over FY2011. The operating loss of the company was $47.3 million in FY2012, as compared to an operating loss of $44.3 million over FY2011. The net loss was $47.1 million in FY2012, as compared to a net loss of $44.2 million over FY2011. Reasons to Purchase: - Gain understanding of Achillion Pharmaceuticals, Inc. and the factors that influence its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess Achillion Pharmaceuticals, Inc. as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on Achillion Pharmaceuticals, Inc.’s business structure, strategy and prospects